Page last updated: 2024-10-31

mitoxantrone and Local Neoplasm Recurrence

mitoxantrone has been researched along with Local Neoplasm Recurrence in 148 studies

Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.

Research Excerpts

ExcerptRelevanceReference
"We treated elderly patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) using a CMD (CPT-11, mitoxantrone [MIT], dexamethasone [DEX]) regimen and studied its safety and efficacy."9.12Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. ( Bessho, M; Higashihara, M; Kohori, M; Niitsu, N, 2007)
" In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%."9.12Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. ( Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ, 2007)
"To investigate the safety and feasibility of a novel form of treatment offered by the direct intraoperative application of a Surgifoam-mitoxantrone mix into a glioblastoma multiforme postresection cavity."9.12Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. ( Boiardi, A; Broggi, G; Broggi, M; Ferroli, P; Franzini, A; Lamperti, M; Maccagnano, E, 2006)
"The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects."9.11Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. ( Deliveliotis, C; Dimopoulos, C; Giannopoulos, A; Papatsoris, AG, 2004)
"This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection."9.10A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. ( Chen, WH; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Lin, CC; Liu, JP; Wang, CH, 2003)
"Fourteen patients with recurrent breast cancer were treated with a combination of mitoxantrone (10 mg/m2 iv, day 1), vincristine (1 mg/m2 iv, day 1) and prednisolone (30 mg/day day 1-7)."9.08[Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer]. ( Fukunaga, M; Iba, T; Kidokoro, A; Momose, F; Yagi, Y, 1995)
"Randomized clinical trials were conducted in patients with advanced/relapsed breast cancer, using CMitF (mitoxantrone, cyclophosphamide, and 5-fluorouracil) regimen in comparison with CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen."9.06[Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer]. ( Sakai, K; Taguchi, T; Terasawa, T; Wada, H, 1986)
"Combination treatment with mitoxantrone hydrochloride, vincristine sulfate and prednisolone is an effective treatment for breast cancer."7.72Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer. ( Aoki, T; Katsumata, K; Koyanagi, Y; Kusama, M; Tomioka, H, 2003)
"The authors examined the survival rates of 60 patients with breast cancer who underwent parasternal lymph node biopsy during surgery with axillary lymph node dissection and had histologically confirmed axillary node metastasis followed by adjuvant doxorubicin- or mitoxantrone-containing combination chemotherapy to ascertain whether administration of anthracycline or its analogue improved the prognosis of both axillary and parasternal node-positive patients."7.70Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy. ( Kanno, M; Nakamura, S; Noguchi, M; Terasaki, Y; Tsugawa, K; Uotani, C; Yamanaka, S, 2000)
"Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective."7.70[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000)
" Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present."7.69Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994)
"We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i."7.69[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997)
"We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas."7.69Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. ( Boiardi, A; Broggi, G; Pozzi, A; Salmaggi, A; Silvani, A, 1996)
"To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)."7.68A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990)
"Intensive sequential chemotherapy with mitoxantrone, 12 mg/m2/d on days 1 through 3, etoposide, 200 mg/m2/d as a continuous infusion on days 8 through 10, and cytarabine, 500 mg/m2/d as a continuous infusion on days 1 through 3 and 8 through 10 was administered to 72 patients aged less than 60 years with previously treated acute myelogenous leukemia (AML)."7.68Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. ( Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P, 1991)
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed."7.67[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984)
"The effects of combination chemotherapy including mitoxantrone (MXN) "M-VEMFH" for advanced breast cancer were studied."7.67[Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer]. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sugiura, I, 1985)
"Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)."7.66Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983)
"In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life."6.705'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001)
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."6.67Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)
"Multiple myeloma has low complete remission rate and high recurrence rate."5.33[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. ( Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y, 2005)
"Concomitant radiotherapy with adjuvant fluorouracil, mitoxantrone, and cyclophosphamide has significantly better locoregional control in node-positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity."5.12A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. ( Bertheault-Cvitkovic, F; Castèra, D; Combe, M; de la Lande, B; Demange, L; Garbay, JR; Graïc, Y; Krzisch, C; Leduc, B; Lucas, V; Mouret-Fourme, E; Nguyen, TD; Noguès, C; Rouëssé, J; Serin, D; Villet, R, 2006)
"To investigate the safety and feasibility of a novel form of treatment offered by the direct intraoperative application of a Surgifoam-mitoxantrone mix into a glioblastoma multiforme postresection cavity."5.12Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. ( Boiardi, A; Broggi, G; Broggi, M; Ferroli, P; Franzini, A; Lamperti, M; Maccagnano, E, 2006)
"We treated elderly patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) using a CMD (CPT-11, mitoxantrone [MIT], dexamethasone [DEX]) regimen and studied its safety and efficacy."5.12Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. ( Bessho, M; Higashihara, M; Kohori, M; Niitsu, N, 2007)
"Of our study was to assess and compare the outcome of patients undergoing anthracycline based neoadjuvant chemotherapy in locally advanced primary breast cancers with patients receiving mitoxantrone, methotrexate and mitomycin (MMM) as neoadjuvant agents."5.12Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience. ( Agrawal, A; Asgeirsson, KS; Chan, SY; Cheung, KL; Ellis, IO; Mathew, J; Mukherjee, A; Robertson, JF, 2007)
" In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%."5.12Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. ( Briel, J; Colevas, AD; Gore, SD; Greer, J; Hattenburg, C; Jones, RJ; Karp, JE; Levis, MJ; Smith, BD; Wright, JJ, 2007)
"The two doses of mitoxantrone resulted in similar efficacy for the prevention of superficial bladder cancer recurrences, with the dose of 10 mg of mitoxantrone being related to fewer side effects."5.11Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study. ( Deliveliotis, C; Dimopoulos, C; Giannopoulos, A; Papatsoris, AG, 2004)
"Twenty-three patients with multifocal superficial bladder cancer (stage Ta - T1) unresponsive to at least 3 different intravesical agents, were enrolled in a phase II study in order to evaluate the prophylactic effects of intravesical Mitoxantrone (20 mg) after complete endoscopic resection (TUR) of any papillary tumor."5.10[Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study]. ( Abatangelo, G; Bassi, PF; Carando, R; Dal Moro, F; Piazza, N; Spinadin, R; Tavolini, IM, 2003)
"This randomized trial was conducted to compare the efficacy and side effects of intravesical mitoxantrone instillation with those of doxorubicin in superficial bladder cancer following transurethral resection."5.10A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer. ( Chen, WH; Huang, JS; Lai, CH; Lan, YJ; Liaw, CC; Lin, CC; Liu, JP; Wang, CH, 2003)
"Thirty cases (breast cancer-20 cases, malignant lymphoma-4 cases, different malignancies-6 cases) of histologically/cytologically verified malignant pleural effusion (MPE) in 29 patients were treated with intrapleurally instilled mitoxantrone (30 mg)."5.08Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study. ( Aasebø, U; Norum, J; Sager, G; Slørdal, L, 1997)
"Fourteen patients with recurrent breast cancer were treated with a combination of mitoxantrone (10 mg/m2 iv, day 1), vincristine (1 mg/m2 iv, day 1) and prednisolone (30 mg/day day 1-7)."5.08[Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer]. ( Fukunaga, M; Iba, T; Kidokoro, A; Momose, F; Yagi, Y, 1995)
"In a non-randomized clinical trial, combined intraperitoneal therapy with recombinant interferon alpha-2b (20-50 MU) and mitoxantrone (20-50 mg) was studied for recurrent ovarian cancer with ascites."5.07Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer. ( Gröhn, P; Kivinen, S; Mäenpää, J; Räisänen, I; Sipilä, P; Väyrynen, M, 1994)
"Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks."5.06Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group. ( Adcock, L; Beecham, J; Bundy, BN; Muss, HB, 1990)
"Randomized clinical trials were conducted in patients with advanced/relapsed breast cancer, using CMitF (mitoxantrone, cyclophosphamide, and 5-fluorouracil) regimen in comparison with CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen."5.06[Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer]. ( Sakai, K; Taguchi, T; Terasawa, T; Wada, H, 1986)
"The efficacy of fludarabine in combination with an intermediate dose of cytosine arabinoside, mitoxantrone, and G-CSF (FLANG; fludarabine 30 mg/m(2)/day, cytosine arabinoside 1 g/m(2)/day, mitoxantrone 10 mg/m(2)/day, and G-CSF 300 μg/day for 5 days) was evaluated in patients with refractory or relapsed acute myelogenous leukemia (AML)."3.77FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. ( Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS, 2011)
"Combination treatment with mitoxantrone hydrochloride, vincristine sulfate and prednisolone is an effective treatment for breast cancer."3.72Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer. ( Aoki, T; Katsumata, K; Koyanagi, Y; Kusama, M; Tomioka, H, 2003)
"We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery."3.70Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999)
"Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective."3.70[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000)
"The authors examined the survival rates of 60 patients with breast cancer who underwent parasternal lymph node biopsy during surgery with axillary lymph node dissection and had histologically confirmed axillary node metastasis followed by adjuvant doxorubicin- or mitoxantrone-containing combination chemotherapy to ascertain whether administration of anthracycline or its analogue improved the prognosis of both axillary and parasternal node-positive patients."3.70Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy. ( Kanno, M; Nakamura, S; Noguchi, M; Terasaki, Y; Tsugawa, K; Uotani, C; Yamanaka, S, 2000)
"We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i."3.69[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997)
" Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present."3.69Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. ( Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994)
"Following local treatment and doxorubicin-containing standard chemotherapy, 42 patients with surgical Stage II or IIIA breast cancer containing ten or more involved axillary nodes and 13 patients with Stage IIIB disease were treated with high-dose chemotherapy (TMJ) consisting of thiotepa (750 mg/m2), mitoxantrone (40 mg/m2), and carboplatin (1000 mg/m2), with autologous bone marrow (ABM) and peripheral stem cell (PSC) transplant, followed by irradiation and/or hormone therapy."3.69TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. ( Ahmed, T; Beer, M; Cook, P; Feldman, EJ; Lake, DE; Mittelman, A; Puccio, C; Razis, ED; Samonis, G, 1994)
"We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas."3.69Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. ( Boiardi, A; Broggi, G; Pozzi, A; Salmaggi, A; Silvani, A, 1996)
"To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML)."3.69Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. ( Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F, 1995)
"Thirty-nine women (aged 31-82 years) with recurrent breast cancer underwent superselective IAC (25 mg/m2 mitoxantrone hydrochloride every 24 hours) through the subclavian artery branches after heparin administration."3.69Previously treated, locally recurrent breast cancer: treatment with superselective intraarterial chemotherapy. ( Brambs, HJ; Doma, A; Görich, J; Hasan, I; Kunze, V; Majdali, R; Reiser, M; Sittek, H, 1995)
"Fifty-three metastatic breast cancer patients were treated with a four-drug program of high-dose chemotherapy including cyclophosphamide (6 g/m2), thiotepa (500 mg/m2), carboplatin (800-1,600 mg/m2) and mitoxantrone (20-60 mg/m2) with autologous peripheral blood progenitor cell support followed by filgrastim."3.69[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer]. ( Alonso, JL; Ayala, F; Casado, A; Díaz-Rubio, E; Llorente, L; López Martín, JA; Martín, M; Nieto, Y; Pérez Calvo, J; Pérez López, C; Rodríguez Lescure, A; Villegas, A, 1997)
"Transcatheter arterial chemotherapy with mitoxantrone was carried out in 9 patients suffering from advanced breast cancer."3.68[Intra-arterial chemotherapy in locally advanced breast carcinomas]. ( Brambs, HJ; Görich, J; Kauffmann, GW; Kaufmann, M; Richter, GM; Roeren, T; Schmid, H, 1991)
"Forty-two patients with locally advanced breast cancer (n = 8) or recurrent breast cancer (n = 34) received regional chemotherapy (mitoxantrone 25 mg/m2 per 24 h) via the internal mammary artery or other vessels of the subclavian artery."3.68[Superselective intra-arterial chemotherapy in breast cancer]. ( Görich, J; Hartlapp, HJ; Hasan, I; Jakschik, J; Reiser, M; Sittek, H; Werner, H, 1993)
"Intensive sequential chemotherapy with mitoxantrone, 12 mg/m2/d on days 1 through 3, etoposide, 200 mg/m2/d as a continuous infusion on days 8 through 10, and cytarabine, 500 mg/m2/d as a continuous infusion on days 1 through 3 and 8 through 10 was administered to 72 patients aged less than 60 years with previously treated acute myelogenous leukemia (AML)."3.68Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. ( Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P, 1991)
"To further improve the effect of high-dose chemotherapy in the treatment of locally advanced and metastatic breast cancer, we sought to develop a second active high-dose noncross-resistant regimen to use in tandem with our customary high-dose regimen of cyclophosphamide, etoposide, and cisplatin (CVP)."3.68A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. ( Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J, 1990)
"The therapeutic effects of 4'-Epi-Adriamycin (Epi-ADR), THP-Adriamycin (THP-ADR) and Mitoxantrone on 30 patients with advanced and recurrent breast cancer were analyzed."3.67[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1984)
"The effects of combination chemotherapy including mitoxantrone (MXN) "M-VEMFH" for advanced breast cancer were studied."3.67[Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer]. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sugiura, I, 1985)
"Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)."3.66Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983)
"The maximum tolerated dose of ixazomib in combination with MEC was 1."2.90A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. ( Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019)
"Current outcome of very early relapse of acute lymphoblastic leukemia (ALL) in children remains poor."2.82A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). ( Baruchel, A; Bertrand, Y; Brethon, B; Cave, H; Galambrun, C; Gandemer, V; Leverger, G; Nelken, B; Plat, G; Rohrlich, P; Schmitt, C; Thomas, C; Vérité, C, 2016)
"The results of this pilot trial suggest that more differentiated dosing schedules based on gender and bone marrow infiltration should be explored for rituximab therapy for lymphoma."2.77Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. ( Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012)
"The interaction of acute myeloid leukemia (AML) blasts with the leukemic microenvironment is postulated to be an important mediator of resistance to chemotherapy and disease relapse."2.77A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. ( Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P, 2012)
"Gemcitabine (G) has shown activity in mantle cell lymphoma (MCL) as a single agent."2.74Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. ( Flynn, PJ; Garbo, LE; Kolibaba, KS; MacRae, MA; Rauch, MA; Wang, Y, 2009)
"This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML)."2.74Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. ( Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC, 2009)
"Primary resistant acute myeloid leukemia (AML) has a very poor prognosis."2.71Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. ( Chelghoum, Y; Elhamri, M; Le, QH; Michallet, M; Revesz, D; Thomas, X, 2003)
"The survival of patients with prostate cancer who relapse after androgen ablation is limited and the therapeutic options are restricted."2.71The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. ( Anagnostopoulos, A; Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kosmidis, P; Samelis, GF; Skarlos, D, 2003)
"Overall response rate was 31% in 26 acute myelogenous leukemia and 12."2.71Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. ( Bauer, KS; Bible, K; Briel, J; Colevas, AD; Garimella, TS; Gojo, I; Gore, SD; Greer, J; Karp, JE; Kaufmann, S; Passaniti, A; Ross, DD; Smith, BD; Tidwell, ML; Wright, JJ, 2005)
"In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life."2.705'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001)
"One patient (1."2.68Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. ( Barraclough, B; Boyages, J; Langlands, AO; Ung, O, 1995)
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."2.67Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. ( Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)
"Mitoxantrone is an active and relatively non-toxic agent which merits further assessment prior to its incorporation in first-line therapy of acute leukaemia."2.65Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1983)
"Recent advances have been made in the treatment of pancreas cancer."2.42[Adjuvant and additive therapy for cancer of the pancreas]. ( Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD, 2003)
"A 47 year old woman with a MALT lymphoma affecting the breast exclusively is reported."2.40[Primary MALT-type lymphoma of the breast]. ( Campo, E; Cervantes, F; Esteve, J; Montserrat, E; Rafel, M; Serra, A; Velasco, M, 1998)
"The term "hormone-refractory" prostate cancer has evolved to include patients with a spectrum of diseases."2.39Hormone-refractory (D3) prostate cancer: refining the concept. ( Kelly, WK; Scher, HI; Steineck, G, 1995)
"Bortezomib is a proteasome inhibitor with activity in pediatric acute lymphoblastic leukemia."1.56Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib. ( August, KJ; Gamis, AS; Guest, EM; Hays, JA; Lewing, K, 2020)
"Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT)."1.43High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. ( Aurer, I; Bašić-Kinda, S; Dotlić, S; Dujmović, D; Kralik, M; Labar, B; Mazić, S; Mitrović, Z; Nemet, D; Radman, I; Šantek, F; Sertić, D, 2016)
"There were 32 small lymphocytic lymphomas and 111 marginal zone lymphomas."1.42Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. ( Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL, 2015)
"Multiple myeloma has low complete remission rate and high recurrence rate."1.33[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. ( Hong, WD; Li, J; Luo, SK; Tong, XZ; Zhao, Y, 2005)
"A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation."1.33Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. ( Kara, B; Kara, IO; Paydas, S; Sahin, B, 2005)
"Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup."1.29Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996)
"Responses of the Hodgkin's disease to this therapy were favourable but short-lived."1.28High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Baglin, TP; Flavell, DJ; Flavell, SU; Lim, SH; Marcus, RE; Wimperis, JZ, 1992)
"Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia."1.28Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. ( Choi, KE; Daley, KM; Kaminer, LS; Larson, RA, 1990)
" The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m2/day to 24 mg/m2/day, and finally to 28 mg/m2/day to determine the maximum tolerated dose for this chemotherapy combination."1.28Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. ( Amrein, PC; Davis, RB; Mayer, RJ; Schiffer, CA, 1990)
"Mitoxantrone was administered to 12 patients with advanced or recurrent endometrial carcinoma of whom only 1 had received prior chemotherapy (chlorambucil)."1.27Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma. ( Boadle, DJ; Tattersall, MH, 1987)
"Two percent had congestive heart failure associated with doxorubicin."1.27Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985)

Research

Studies (148)

TimeframeStudies, this research(%)All Research%
pre-199015 (10.14)18.7374
1990's60 (40.54)18.2507
2000's49 (33.11)29.6817
2010's21 (14.19)24.3611
2020's3 (2.03)2.80

Authors

AuthorsStudies
Kopmar, NE1
Gooley, T1
Curley, N1
Russell, K1
Shaw, C1
Schonhoff, K1
Lim, J1
Halpern, AB1
Walter, RB1
Scott, BL1
Appelbaum, J1
Hendrie, PC1
Estey, EH1
Percival, MM1
Peñalver, FJ1
Márquez, JA1
Durán, S1
Giraldo, P1
Martín, A1
Montalbán, C1
Sancho, JM1
Ramírez, MJ1
Terol, MJ1
Capote, FJ1
Gutiérrez, A1
Sánchez, B1
López, A1
Salar, A1
Rodríguez-Caravaca, G1
Canales, M1
Caballero, MD1
August, KJ1
Guest, EM1
Lewing, K1
Hays, JA1
Gamis, AS1
Ruan, M1
Liu, LP1
Zhang, AL1
Quan Qi, B1
Liu, F1
Liu, TF1
Liu, XM1
Chen, XJ1
Yang, WY1
Guo, Y1
Zhang, L1
Zou, Y1
Chen, YM1
Zhu, XF1
Nakamura, S2
Kawaguchi, K1
Fukui, T1
Hakiri, S1
Ozeki, N1
Mori, S1
Goto, M1
Hashimoto, K1
Ito, T1
Yokoi, K1
Advani, AS1
Cooper, B1
Visconte, V1
Elson, P1
Chan, R1
Carew, J1
Wei, W1
Mukherjee, S1
Gerds, A1
Carraway, H1
Nazha, A1
Hamilton, B1
Sobecks, R2
Caimi, P1
Tomlinson, B1
Malek, E1
Little, J1
Miron, A1
Pink, J1
Maciejewski, J1
Unger, A1
Kalaycio, M2
de Lima, M1
Sekeres, MA2
Lafrenie, RM1
Speigl, L1
Buckner, CA1
Pawelec, G1
Conlon, MS1
Shipp, C1
Lowry, L1
Smith, P1
Cunningham, D1
Linch, DC1
Zinzani, PL1
Pellegrini, C1
Broccoli, A1
Gandolfi, L1
Stefoni, V1
Casadei, B1
Maglie, R1
Argnani, L1
Pileri, S2
Thiel, A1
Schetelig, J1
Pönisch, W1
Schäfer-Eckart, K1
Aulitzky, W1
Peter, N1
Schulze, A1
Maschmeyer, G2
Neugebauer, S1
Herbst, R2
Hänel, A2
Morgner, A1
Kroschinsky, F2
Bornhäuser, M1
Lange, T1
Wilhelm, M1
Niederwieser, D1
Ehninger, G2
Fiedler, F2
Hänel, M2
Cohen, JB1
Bucur, S1
Winton, EF1
Sinha, R1
Heffner, LT1
King, N1
Lonial, S1
Langston, AA1
Waller, EK1
Hutchison-Rzepka, A1
Colbert, A1
Lechowicz, MJ1
Flowers, CR1
Nelken, B1
Cave, H1
Leverger, G1
Galambrun, C1
Plat, G1
Schmitt, C1
Thomas, C1
Vérité, C1
Brethon, B1
Gandemer, V1
Bertrand, Y1
Baruchel, A1
Rohrlich, P1
Aurer, I1
Nemet, D1
Mitrović, Z1
Dujmović, D1
Bašić-Kinda, S1
Radman, I1
Sertić, D1
Šantek, F1
Kralik, M1
Dotlić, S1
Mazić, S1
Labar, B1
Tang, YL1
Chia, WK1
Yap, EC1
Julia, MI1
Leong, CF1
Salwati, S1
Wong, CL1
Rashed, WM1
Zekri, W1
Awad, M1
Taha, H1
Abdalla, B1
Alfaar, AS1
Lee, SS1
Lee, JH2
Kim, DY1
Kim, SH1
Lim, SN1
Lee, YS1
Seol, M1
Ryu, SG1
Kang, YA1
Jang, S1
Park, CJ1
Chi, HS1
Yun, SC1
Lee, KH1
Garbo, LE1
Flynn, PJ1
MacRae, MA1
Rauch, MA1
Wang, Y1
Kolibaba, KS1
Hogg, ME1
Popowich, DA1
Wang, EC1
Kiel, KD1
Stryker, SJ1
Halverson, AL1
Brady, AK1
Fu, AZ1
Earl, M1
Advani, A1
Saunthararajah, Y1
Copelan, E1
Eom, KS1
Min, WS1
Kim, HJ1
Cho, BS1
Choi, SM1
Lee, DG1
Lee, S1
Min, CK1
Kim, YJ1
Cho, SG1
Lee, JW1
Kim, CC1
Wei, A1
Teh, TC1
Price, SL1
Lancet, JE1
George, TJ1
Wetzstein, GA1
List, AF2
Ho, VQ1
Fernandez, HF1
Pinilla-Ibarz, J1
Kharfan-Dabaja, MA1
Komrokji, RS1
Machaczka, M1
Nahi, H1
Karbach, H1
Klimkowska, M1
Hägglund, H1
Molitor, B1
Börgermann, C1
Uy, GL1
Rettig, MP1
Motabi, IH1
McFarland, K1
Trinkaus, KM1
Hladnik, LM1
Kulkarni, S1
Abboud, CN1
Cashen, AF1
Stockerl-Goldstein, KE1
Vij, R1
Westervelt, P1
DiPersio, JF1
Jäger, U1
Fridrik, M1
Zeitlinger, M1
Heintel, D1
Hopfinger, G1
Burgstaller, S1
Mannhalter, C1
Oberaigner, W1
Porpaczy, E1
Skrabs, C1
Einberger, C1
Drach, J1
Raderer, M1
Gaiger, A1
Putman, M1
Greil, R1
Filleron, T1
Kramar, A1
Dalenc, F1
Spielmann, M1
Fumoleau, P1
Kerbrat, P1
Martin, AL1
Roché, H1
Büchler, T1
Ferra, C1
Virgili, N1
Montanya, E1
Grañena, A1
Neoptolemos, JP1
Raraty, MG1
Ghaneh, P1
Hickey, H1
Stocken, DD1
Dunn, JA1
Friess, H1
Büchler, MW1
Huang, JS1
Chen, WH1
Lin, CC1
Liaw, CC1
Wang, CH1
Lan, YJ1
Lai, CH1
Liu, JP1
Katsumata, K2
Tomioka, H1
Kusama, M2
Aoki, T1
Koyanagi, Y2
Samelis, GF1
Skarlos, D1
Bafaloukos, D1
Kosmidis, P1
Anagnostopoulos, A1
Aravantinos, G1
Dimopoulos, MA1
Revesz, D1
Chelghoum, Y2
Le, QH1
Elhamri, M2
Michallet, M3
Thomas, X2
Ring, A1
Webb, A1
Ashley, S2
Allum, WH1
Ebbs, S2
Gui, G1
Sacks, NP1
Walsh, G2
Smith, IE1
Bassi, PF1
Spinadin, R1
Carando, R1
Dal Moro, F1
Abatangelo, G1
Piazza, N1
Tavolini, IM1
Calais, G4
Papatsoris, AG1
Deliveliotis, C1
Giannopoulos, A1
Dimopoulos, C1
Boiardi, A8
Bartolomei, M2
Silvani, A7
Eoli, M6
Salmaggi, A7
Lamperti, E4
Milanesi, I2
Botturi, A4
Rocca, P1
Bodei, L1
Broggi, G8
Paganelli, G1
Le, Q1
Botton, Sd1
Raffoux, E1
Pautas, C1
Dreyfus, F2
Dhedin, N1
Vekhoff, A1
Troncy, J1
Pigneux, A1
Revel, Td1
Reman, O1
Travade, P2
Thiebaut, A1
Guerci, A2
Fenaux, P2
Dombret, H1
Kara, IO1
Sahin, B1
Paydas, S1
Kara, B1
Bao, L1
Jiang, B1
Huang, XJ1
Wang, DB1
Qiu, JY1
Lu, XJ1
Lu, J1
Shi, HX1
Wang, FR1
Lu, DP1
Bissola, L1
Finocchiaro, G1
Karp, JE2
Passaniti, A1
Gojo, I1
Kaufmann, S1
Bible, K1
Garimella, TS1
Greer, J2
Briel, J2
Smith, BD2
Gore, SD2
Tidwell, ML1
Ross, DD1
Wright, JJ2
Colevas, AD2
Bauer, KS1
Luo, SK1
Li, J1
Hong, WD1
Zhao, Y1
Tong, XZ1
Rouëssé, J1
de la Lande, B1
Bertheault-Cvitkovic, F1
Serin, D3
Graïc, Y1
Combe, M1
Leduc, B1
Lucas, V1
Demange, L1
Nguyen, TD1
Castèra, D1
Krzisch, C1
Villet, R1
Mouret-Fourme, E1
Garbay, JR1
Noguès, C1
Nakabayashi, M1
Oh, WK1
Toledano, A2
Garaud, P2
Fourquet, A2
Bosset, JF2
Breteau, N1
Body, G2
Azria, D2
Le Floch, O3
Ferroli, P1
Broggi, M1
Franzini, A1
Maccagnano, E1
Lamperti, M1
Niitsu, N2
Kohori, M1
Higashihara, M1
Bessho, M1
Miny-Buffet, J1
Favre, A1
Mathew, J1
Asgeirsson, KS1
Agrawal, A1
Mukherjee, A1
Ellis, IO1
Cheung, KL2
Chan, SY2
Robertson, JF2
Levis, MJ1
Hattenburg, C1
Jones, RJ1
Isogai, R1
Fukao, M1
Kawada, A1
Izumi, K1
Kanno, H1
Umemoto, S1
Hasumi, H1
Osada, Y1
Otai, J1
Mikata, K1
Tsuchiya, F1
Nagashima, Y1
Lü, SQ1
Yang, JM1
Song, XM1
Chen, L1
Zhang, WP1
Ni, X1
Xu, XQ1
Wang, JM1
Gaviani, P1
Fiumani, A1
Falcone, C1
Solari, A1
Filippini, G1
Di Meco, F1
Prentice, HG1
Robbins, G1
Ma, DD1
Ho, AD1
Tominaga, T1
Kitamura, M1
Hayashi, K1
Takahashi, I1
Kosaki, G1
Paciucci, PA1
Ohnuma, T1
Cuttner, J1
Silver, RT1
Holland, JF1
Maffezzini, M1
Simonato, A1
Zanon, M1
Raber, M1
Carmignani, G1
Merlin, JL1
Missoum, N1
Feldmann, L1
Marchal, S1
Witz, F1
Rose, C2
Guerci, O1
Görich, J4
Hasan, I2
Majdali, R1
Sittek, H2
Kunze, V2
Doma, A1
Reiser, M2
Brambs, HJ3
Namasivayam, S1
Whelan, P1
Scher, HI1
Steineck, G1
Kelly, WK1
Lob, S1
Bergmann, L1
Müller, H1
Jacobi, V1
Hoelzer, D1
Flamm, J1
Donner, G1
Oberleitner, S1
Hausmann, R1
Havelec, L1
Doughty, JC1
McCarter, DH1
Reid, AW1
Kane, E1
McArdle, CS1
Stiff, P1
Bayer, R1
Camarda, M1
Tan, S1
Dolan, J1
Potkul, R1
Loutfi, S1
Kinch, L1
Sosman, J1
Peace, D1
Iba, T1
Yagi, Y2
Kidokoro, A1
Fukunaga, M1
Momose, F1
Ung, O1
Langlands, AO1
Barraclough, B1
Boyages, J1
Razis, ED1
Samonis, G1
Cook, P1
Beer, M1
Mittelman, A1
Lake, DE1
Feldman, EJ1
Puccio, C1
Ahmed, T1
Berger, C1
Descamps, P1
Chapet, S1
Reynaud-Bougnoux, A1
Bougnoux, P1
Lansac, J1
Cabanillas, F3
Rodriguez, MA1
Hagemeister, FB2
Purugganan, R1
Fuller, L1
McLaughlin, P1
Swan, F1
Romaguera, J1
Rodriguez, M1
Mäenpää, J1
Kivinen, S1
Räisänen, I1
Sipilä, P1
Väyrynen, M1
Gröhn, P1
Dufour, P1
Bergerat, JP1
Barats, JC1
Giron, C1
Duclos, B1
Dellenbach, P1
Ritter, J1
Renaud, R1
Audhuy, B1
Oberling, F1
Cherqui, D1
Piedbois, P1
Pierga, JY1
Duvoux, C1
Vavasseur, D1
Tran Van-Nhieu, J1
LeBourgeois, JP1
Julien, M1
Fagniez, PL1
Dhumeaux, D1
Lorusso, V1
Catino, A1
Gargano, G1
Fioretto, A1
Berardi, F1
de Lena, M1
Serretta, V1
Corselli, G1
Pavone, C1
Pavone-Macaluso, M1
Tarraza, HM1
Boyce, CR1
Smith, WG1
Jones, MA1
Jakschik, J1
Werner, H1
Hartlapp, HJ1
Newling, DW1
Brensing, KA1
Sokiranski, R1
Rilinger, N1
Müller-Miny, H1
van Bree, C1
Schopman, EM1
Bakker, PJ1
Kipp, JB1
Barendsen, GW1
Spier, CS1
Grogan, TM1
Johnson, C1
Roe, DJ1
Greer, JP1
Wolff, SN1
Broxterman, HJ1
Scheffer, GL2
Scheper, RJ2
Dalton, WS1
Haas, R1
Moos, M1
Möhle, R1
Döhner, H1
Witt, B1
Goldschmidt, H1
Murea, S1
Flentje, M1
Wannenmacher, M1
Hunstein, W1
Salutari, P1
Micciulli, G1
Chiusolo, P1
Tommasi, M1
Di Mario, A1
Sica, S1
Leone, G1
Pozzi, A2
Aasebø, U1
Norum, J1
Sager, G1
Slørdal, L1
Abubakar, AA1
Riches, AC1
Kahles, H1
Bastian, HJ1
Schiffmann, O1
Geck, M1
Helmke, FR1
Golz, N1
Hartmann, KA1
Audretsch, W1
Carl, UM1
Gripp, S1
Kolotas, C1
Muskalla, K1
Rezai, M1
Schnabel, T2
Waap, I1
Zamboglou, N2
Schmitt, G2
Gondo, H1
Harada, M1
Miyamoto, T1
Takenaka, K1
Tanimoto, K1
Mizuno, S1
Fujisaki, T1
Nagafuji, K1
Hayashi, S1
Eto, T1
Taniguchi, S1
Akashi, K1
Harada, N1
Yamasaki, K1
Shibuya, T1
Matsuishi, E1
Ohno, Y1
Makino, S1
Takamatsu, Y1
Murakawa, M1
Teshima, T1
Hirota, Y1
Okamura, T1
Kinukawa, N1
Niho, Y1
Yamamoto, K1
Shibata, K1
Murano, A1
Kawasaki, M1
Moriwaki, R1
Nagakawa, Y1
Ogata, T1
Ellis, P1
Smith, I1
Baum, M1
Sacks, N1
McKinna, J1
Martín, M1
Casado, A1
Llorente, L1
López Martín, JA1
Rodríguez Lescure, A1
Nieto, Y1
Ayala, F1
Pérez Calvo, J1
Alonso, JL1
Pérez López, C1
Villegas, A1
Díaz-Rubio, E1
Rafel, M1
Esteve, J1
Cervantes, F1
Velasco, M1
Serra, A1
Campo, E1
Montserrat, E1
Sanna, P1
Van den Bosch, S1
Cavalli, F1
Ghielmini, M1
Robak, T1
Gora-Tybor, J1
Urbańska-Ryś, H1
Krykowski, E1
Husain, A1
Sabbatini, P1
Spriggs, D1
Fennelly, D1
Aghajanian, C1
Barakat, R1
Curtin, J1
Venkatraman, E1
Hoskins, W3
Markman, M3
Sternberg, DW1
Aird, W1
Neuberg, D1
Thompson, L1
MacNeill, K1
Amrein, P1
Shulman, LN1
Matsuoka, T1
Nomizu, T1
Yabuta, T1
Katagata, N1
Watanabe, F1
Yamaki, Y1
Tsuchiya, A1
Takenoshita, S1
Eilber, FC1
Rosen, G1
Forscher, C1
Nelson, SD1
Dorey, F1
Eilber, FR1
Kanno, M1
Uotani, C1
Yamanaka, S1
Terasaki, Y1
Tsugawa, K1
Noguchi, M1
Sato , K1
Hiraide, H1
Tamakuma, S1
Tabei, T1
Maruyama, M1
Touma, M1
Okamura, H1
Matsumoto, F1
Akao, S1
Ishikawa, H1
Mochizuki, H1
Ruiz Hernández, G1
Pallardó-Calatayud, J1
Ferrer Albiach, C1
Balaguer-Martínez, JV1
Romero-de-Avila, C1
Castillo-Pallarés, FJ1
Thurnher, D1
Kornfehl, J2
Burian, M2
Gedlicka, C2
Selzer, E2
Quint, C1
Neuchrist, C1
Kornek, GV2
Kröger, N1
Birkmann, J1
Naumann, R1
Friedrichsen, K1
Zander, AR1
Iijima, K1
Chizuka, A1
DiPaola, RS1
Chenven, ES1
Shih, WJ1
Lin, Y1
Amenta, P1
Goodin, S1
Shumate, A1
Capanna, T1
Cardiella, M1
Cummings, KB1
Aisner, J1
Todd, MB1
Tan, SM1
Willsher, PC1
Blamey, RW1
Zappacosta, B1
Fariselli, L1
Wilder, RB1
Schlembach, PJ1
Jones, D1
Chronowski, GM1
Ha, CS1
Younes, A1
Barista, I1
Cox, JD1
van der Kolk, DM1
Vellenga, E1
Müller, M1
Bates, SE1
de Vries, EG1
Schüll, B1
Formanek, M1
Knerer, B1
Scheithauer, W1
Chisesi, T1
Federico, M1
Levis, A1
Deliliers, GL1
Gobbi, PG1
Santini, G1
Luminari, S1
Linfomi, MB1
Michieli, M1
Damiani, D1
Geromin, A1
Michelutti, A1
Fanin, R1
Raspadori, D1
Russo, D1
Visani, G1
Dinota, A1
Saglik, Y1
Icli, F1
Uluoglu, O1
Isiklar, ZU1
Lim, SH1
Baglin, TP1
Flavell, DJ1
Flavell, SU1
Wimperis, JZ1
Marcus, RE1
Liso, V1
Specchia, G1
Capalbo, S1
Pavone, V1
Iacobazzi, A1
Iaculli, ML1
Dione, R1
Pansini, N1
Schmid, H1
Roeren, T1
Richter, GM1
Kaufmann, M1
Kauffmann, GW1
Merk, K1
Ideström, K1
Johansson, B1
Kimby, E1
Lindemalm, C1
Osby, E1
Björkholm, M1
Archimbaud, E1
Leblond, V1
Cordonnier, C1
Jaubert, J1
Devaux, Y1
Fiere, D1
Hakes, T2
Reichman, B2
Lewis, JL2
Rubin, S2
Jones, W2
Almadrones, L1
Fornasiero, A1
Daniele, O1
Ghiotto, C1
Piazza, M1
Fiore-Donati, L1
Calabró, F1
Rea, F1
Fiorentino, MV1
Wallerstein, R1
Spitzer, G1
Dunphy, F1
Huan, S1
Hortobagyi, G1
Yau, J1
Buzdar, A1
Holmes, F1
Theriault, R1
Ewer, M1
Muss, HB1
Bundy, BN1
Adcock, L1
Beecham, J1
Kober, F1
Heiss, A1
Keminger, K1
Depisch, D1
Hiddemann, W1
Aul, HC1
Urbanitz, D1
Lathan, B1
Reichle, A1
Köppler, H1
Donhuijsen-Ant, R1
Ludwig, WD1
Grüneisen, T1
Stewart, DJ2
Green, R1
Futter, N1
Walsh, W1
McKay, D1
Verma, S1
Maroun, JA2
Redmond, D1
Marit, G1
Cony, P1
Duclos, F1
Puntous, M1
Broustet, A1
Reiffers, J1
Kaminer, LS1
Choi, KE1
Daley, KM1
Larson, RA1
Amrein, PC1
Davis, RB1
Mayer, RJ1
Schiffer, CA1
Kuhn, K1
Purea, H1
Selbach, J1
Westerhausen, M1
Evensen, SA1
Brinch, L1
Wisløff, F1
Werner, A1
Diedrich, K1
Krebs, D1
Bode, U1
Musch, E1
Boadle, DJ1
Tattersall, MH1
Taguchi, T1
Sakai, K1
Terasawa, T1
Wada, H1
Charrot, P1
Chevrier, A1
Cripps, C1
Hilgers, RD1
Von Hoff, DD1
Stephens, RL1
Boutselis, JG1
Hørding, U1
Jakobsen, K1
Dirksen, H1
Buzdar, AU1
Marcus, C1
Smith, TL1
Blumenschein, GR1
Ito, Y1
Hoshino, A1
Ohara, K1
Kamiya, O1
Nagata, K1
Kojima, T1
Kinoshita, T1
Sugiura, I1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed[NCT01133158]Phase 261 participants (Actual)Interventional2009-07-31Completed
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability[NCT00208975]Phase 215 participants (Actual)Interventional2002-07-31Terminated (stopped due to slow accrual)
an Single Center,Single Arm, Phase 3 Study to Evaluate Efficacy and Safety of PD-1 Inhibitor Combined With Azacytidine and HAG Regimen for Patients With Relapsed or Refractory Acute Myeloid Leukemia.[NCT04722952]Phase 330 participants (Anticipated)Interventional2021-05-01Recruiting
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study[NCT02605460]Phase 220 participants (Anticipated)Interventional2014-02-28Recruiting
A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML[NCT00512252]Phase 1/Phase 252 participants (Actual)Interventional2007-07-31Completed
Multicenter Study to Evaluate the Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy Und Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma[NCT01560117]Phase 229 participants (Actual)Interventional2004-01-31Completed
Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma[NCT00002474]Phase 20 participants Interventional1991-02-28Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]Phase 211 participants (Actual)Interventional2010-10-14Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Response Rate

"The primary endpoint is the number of Participants with Response according to the criteria of the International Workshop to Standardize Response Criteria for NHL~Complete Remission (CR):~Nodes returned to normal (if GTD >15 mm before therapy, GTD now ≤15 mm; if GTD 11-15 and SA >10 mm before therapy, SA now ≤10 mm) All (non-nodal) target lesions completely resolved~Partial Remission (PR) SPD of target lesions decreased ≥50% from baseline Spleen and liver nodules regress by 50% in SPD or single lesion in GTD~Stable Disease (SD) Not enough shrinkage for PR Not enough growth for PD~Progressive Disease (PD):~SPD increase ≥50% from nadir (smallest value seen during trial) in nodal target lesions overall or in any single nodal target lesion" (NCT01133158)
Timeframe: 7 years

InterventionParticipants (Count of Participants)
Induction Rituximab, Bendamustine, Mitoxantrone, Dexamethasone57
Maintenance Rituximab35

Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.

(NCT01133158)
Timeframe: 7 years

Interventionmonths (Median)
Progression-Free SurvivalDisease-Free SurvivalGlobal SurvivalDuration of the Response
R-BMD5651NA54

Number of Patients's Who Had Complete Response and Partial Response to the Treatment of Fludarabine and Cyclophosphamide Followed by GM-CSF and Rituximab.

"Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of eight weeks and absence of any symptoms related to the tumor.~Partial Response (PR):50% decrease in the sum of the product diameters of all lesions that persist for at least four weeks. No lesion can increase in size and no new lesion can appear during this period.~Stable disease (SD):A tumor that is neither growing nor shrinking.No new tumors have developed" (NCT00208975)
Timeframe: 6 months

,
Interventionparticipants (Number)
Complete ResponsePartial ResponseStable Disease
Chronic Lymphocytic Leukemia421
Non Hodgkin Lymphoma520

Overall Survival

(NCT00512252)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Phase II Dose Treatment37

Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML

A standard 3+3 design was used in the Phase I portion starting with the AMD3100 dose of 80 mcg/kg and escalating by 80 mcg/kg for each successive cohort up to a maximum of 240 mcg/kg/d. The optimal dose was defined as the highest dose of AMD3100 <= 240 mcg/kg at which 0-1 of 6 patients experienced a dose limiting toxicity. (NCT00512252)
Timeframe: Completion of all patients in Phase I portion (232 days)

Interventionmcg/kg (Number)
Phase I Dose Escalation240

Relapse-free Survival

"This is determined only for patients achieving a complete remission. Defined as the interval from the date of the first documentation of a leukemia free state to date of recurrence or death due to any cause.~Kaplain-Meier estimate was used." (NCT00512252)
Timeframe: 1 year

Interventionpercentage of participants (Number)
Phase II Dose Treatment42.9

Time to Neutrophil Recovery

Defined as the date of the first dose of AMD3100 to the date that the absolute neutrophil count >1,000 cells/mm^3. (NCT00512252)
Timeframe: 42 days

Interventiondays (Median)
Phase II Dose Treatment28

Time to Platelet Recovery

Defined as the date of the first dose of AMD3100 to the date that the platelet count is >100,000/mm3 in the absence of platelet transfusions. (NCT00512252)
Timeframe: 42 days

Interventiondays (Median)
Phase II Dose Treatment28.5

Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of AML Blasts (Phase I)

Measured at 0 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after AMD3100 dose on Day 0. (NCT00512252)
Timeframe: Day 0

,,
Interventionpercentage of AML blasts (Median)
AML blasts at 0 hoursAML blasts at 1 hourAML blasts at 2 hoursAML blasts at 4 hoursAML blasts at 6 hoursAML blasts at 8 hoursAML blasts at 12 hoursAML blasts at 24 hours
Phase I Dose Escalation - Dose Level 146.026.026.037.031.032.027.035.0
Phase I Dose Escalation - Dose Level 24.09.037.516.014.019.045.023
Phase I Dose Escalation - Dose Level 343.530.532.530.027.026.035.055

Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of Total Leukocytes (Phase I)

"Measured at 0 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after AMD3100 dose on Day 0.~Characterization of the mobilized cells as well as the kinetics of mobilization will be determined by analyzing the surface expression of mobilized cells by flow cytometry at the specified time points in conjunction with their total leukocyte count from the patient's CBC." (NCT00512252)
Timeframe: Day 0

,,
Interventioncells x 10^3/microliter (Median)
Total leukocytes at 0 hoursTotal leukocytes at 1 hourTotal leukocytes at 2 hoursTotal leukocytes at 4 hoursTotal leukocytes at 6 hoursTotal leukocytes at 8 hoursTotal leukocytes at 12 hoursTotal leukocytes at 24 hours
Phase I Dose Escalation - Dose Level 12.54.344.74.84.55.14.3
Phase I Dose Escalation - Dose Level 24.77.08.59.411.312.012.17.9
Phase I Dose Escalation - Dose Level 33.56.47.58.39.58.97.85.8

Phase II Only: Complete Response Rate of AMD3100 + MEC

"Responses were assessed according to the International Working Group Criteria for AML. All patients who received at least one dose of AMD3100 were considered evaluable for response.~Response rate was the rate of complete remission plus complete remission with incomplete blood count recovery (CR + CRi)." (NCT00512252)
Timeframe: 42 days

,,,
Interventionpercentage of participants (Number)
CR + CRiCR only
>= Second Relapse/Salvage2525
First Relapse, First Salvage5647
Primary Refractory2020
Total4639

Safety and Tolerability of AMD3100 + MEC.

Treatment related mortality (deaths occurring during treatment) (NCT00512252)
Timeframe: 42 days

Interventionparticipants (Number)
SepsisAdverse transfusion reaction w/febrile neutropenia
Phase II Dose Treatment21

Treatment Failure

Treatment failures includes those patients for whom treatment has failed to achieve a CR or a CRi. (NCT00512252)
Timeframe: 42 days

,,,
Interventionparticipants (Number)
Persistent leukemiaDeath during aplasiaUnknown
>= Second Relapse/Salvage300
First Relapse, First Salvage1211
Primary Refractory620
Total2131

Safest Dose of Temozolomide for the DRBEAT Regimen

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

Interventiondose in mg/m^2 (Number)
DRBEAT Regimen773.25

One-year Progression-free Survival and Overall Survival

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

InterventionDays (Median)
Progression Free SurvivalOverall Survival
DRBEAT Regimen132564

Reviews

6 reviews available for mitoxantrone and Local Neoplasm Recurrence

ArticleYear
[Second line therapy for castration-resistant prostate cancer (CRPC)].
    Der Urologe. Ausg. A, 2012, Volume: 51, Issue:3

    Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical

2012
[Adjuvant and additive therapy for cancer of the pancreas].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2003, Volume: 74, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as T

2003
[Radiation and concomitant chemotherapy after surgery for breast cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An

2004
Chemotherapy for high-risk localized prostate cancer.
    BJU international, 2006, Volume: 97, Issue:4

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Mitoxantrone; Neoadjuvant Th

2006
Hormone-refractory (D3) prostate cancer: refining the concept.
    Urology, 1995, Volume: 46, Issue:2

    Topics: Aminoglutethimide; Clinical Trials as Topic; Cortisone; Dexamethasone; Drug Therapy, Combination; Hu

1995
[Primary MALT-type lymphoma of the breast].
    Sangre, 1998, Volume: 43, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph

1998

Trials

53 trials available for mitoxantrone and Local Neoplasm Recurrence

ArticleYear
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
    Leukemia & lymphoma, 2023, Volume: 64, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, A

2023
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase
    Cancer medicine, 2019, Volume: 8, Issue:16

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hyd

2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-15, Volume: 25, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resis

2019
Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra

2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide;

2015
A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Pediatric blood & cancer, 2016, Volume: 63, Issue:2

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides;

2016
Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan

2009
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
    Investigational new drugs, 2009, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti

2009
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin

2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin

2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin

2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
    Blood, 2012, Apr-26, Volume: 119, Issue:17

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamin

2012
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
    Haematologica, 2012, Volume: 97, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols;

2012
A randomized trial comparing intravesical instillations of mitoxantrone and doxorubicin in patients with superficial bladder cancer.
    Chang Gung medical journal, 2003, Volume: 26, Issue:2

    Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Doxorubicin; Female; Humans; Male; Middle

2003
The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Urology, 2003, Volume: 61, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, H

2003
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Annals of hematology, 2003, Volume: 82, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administra

2003
[Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].
    Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2003, Volume: 75, Issue:4

    Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Tran

2003
[Radiation and concomitant chemotherapy after surgery for breast cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An

2004
Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
    Urologia internationalis, 2004, Volume: 72, Issue:4

    Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adj

2004
Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.
    Journal of neuro-oncology, 2005, Volume: 72, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Diseases; Brain Neoplasms; Chemotherapy,

2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Ma

2005
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

2006
Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study.
    International journal of radiation oncology, biology, physics, 2006, Jun-01, Volume: 65, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

2006
New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM).
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Combined Modality

2003
Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.
    Neurosurgery, 2006, Volume: 59, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Br

2006
Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma.
    Cancer science, 2007, Volume: 98, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Disease-Free Surv

2007
Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-01, Volume: 25, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Com

2007
Neoadjuvant chemotherapy in locally advanced primary breast cancers: the Nottingham experience.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007, Volume: 33, Issue:8

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Me

2007
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-01, Volume: 13, Issue:15 Pt 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Fema

2007
Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia.
    Cancer treatment reviews, 1983, Volume: 10 Suppl B

    Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Cells, Cultured; Clinical Trials

1983
Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study.
    British journal of urology, 1995, Volume: 75, Issue:6

    Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Transitional Ce

1995
Adjuvant intravesical mitoxantrone after transurethral resection of primary superficial transitional cell carcinoma of the bladder. A prospective randomised study.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:2

    Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Hu

1995
A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome.
    Gynecologic oncology, 1995, Volume: 57, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Cyc

1995
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S

1995
Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:2

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati

1995
Combined intraperitoneal interferon alpha-2b and mitoxantrone in refractory ovarian cancer.
    Annales chirurgiae et gynaecologiae. Supplementum, 1994, Volume: 208

    Topics: Adult; Aged; Ascites; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administrati

1994
Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission.
    Cancer, 1994, Apr-01, Volume: 73, Issue:7

    Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1994
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmu

1996
Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study.
    Journal of chemotherapy (Florence, Italy), 1997, Volume: 9, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, A

1997
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
    Bone marrow transplantation, 1997, Volume: 20, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Co

1997
Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 1999, Volume: 32, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Dexamethasone; Female; Huma

1999
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Gynecologic oncology, 1999, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disea

1999
5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
    Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

2001
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2001
Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Journal of cancer research and clinical oncology, 2001, Volume: 127, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Fr

2001
Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
    Cancer, 2001, Oct-15, Volume: 92, Issue:8

    Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter

2001
Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast

2001
Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.
    Journal of neuro-oncology, 2001, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Magnetic Re

2001
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
    Cancer, 2002, Mar-15, Volume: 94, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diseas

2002
Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
    Anti-cancer drugs, 2002, Volume: 13, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise

2002
ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13 Suppl 1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Daca

2002
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:6

    Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Injec

1991
Chemotherapy for invasive thymoma. A 13-year experience.
    Cancer, 1991, Jul-01, Volume: 68, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1991
Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group.
    American journal of clinical oncology, 1990, Volume: 13, Issue:1

    Topics: Adult; Aged; Drug Evaluation; Female; Humans; Leiomyosarcoma; Middle Aged; Mitoxantrone; Multicenter

1990
Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-H
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Child

1990
[Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:9

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clini

1986

Other Studies

90 other studies available for mitoxantrone and Local Neoplasm Recurrence

ArticleYear
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bortezomib; Child; Child,

2020
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
    Cancer medicine, 2021, Volume: 10, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cyt

2021
Multimodality therapy for thymoma patients with pleural dissemination.
    General thoracic and cardiovascular surgery, 2019, Volume: 67, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine;

2019
Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
    Clinical breast cancer, 2019, Volume: 19, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; CD8-Positive T

2019
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cau

2013
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
    Hematological oncology, 2015, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva

2015
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma.
    Annals of hematology, 2016, Volume: 95, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female

2016
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
    The Malaysian journal of pathology, 2016, Volume: 38, Issue:3

    Topics: Abnormal Karyotype; Antineoplastic Combined Chemotherapy Protocols; Humans; Idarubicin; In Situ Hybr

2016
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma;

2017
HIV and anal cancer outcomes: a single institution's experience.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:5

    Topics: Antineoplastic Agents; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvan

2009
Race and intensity of post-remission therapy in acute myeloid leukemia.
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black Pe

2011
FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Femal

2011
Salvaging AML with CLAG: novel option, or more of the same?
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colon

2011
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
    Leukemia research, 2011, Volume: 35, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabi

2011
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexame

2012
Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.
    Bulletin du cancer, 2012, Volume: 99, Issue:6

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe

2012
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
    Journal of neuro-oncology, 2002, Volume: 59, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female

2002
Clinical effects of combination therapy with mitoxantrone, vincristine, and prednisolone in breast cancer.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Mitox

2003
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-15, Volume: 21, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

2003
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Mod

2005
Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Heart Neoplasms; Human

2005
[Treatment of refractory and relapsed acute lymphocytic leukemia in adults].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2005, Aug-18, Volume: 37, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male;

2005
Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.
    Journal of neuro-oncology, 2005, Volume: 75, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Dacarbazine; Disease-Free Sur

2005
[Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2005, Volume: 24, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Dexamethasone; Do

2005
Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
    The Journal of dermatology, 2007, Volume: 34, Issue:8

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo

2007
[A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
    Hinyokika kiyo. Acta urologica Japonica, 2007, Volume: 53, Issue:9

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

2007
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:9

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexa

2007
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
    Journal of neuro-oncology, 2008, Volume: 88, Issue:1

    Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi

2008
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Mi

1984
Mitoxantrone in patients with acute leukemia in relapse.
    Cancer research, 1983, Volume: 43, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Child; Drug Administration

1983
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
    The Journal of urology, 1996, Volume: 155, Issue:1

    Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans

1996
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Blood, 1995, Apr-15, Volume: 85, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemot

1995
Previously treated, locally recurrent breast cancer: treatment with superselective intraarterial chemotherapy.
    Radiology, 1995, Volume: 197, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Mitoxantrone;

1995
[Pleomorphic T-cell lymphoma. The diagnostic problems, therapeutic possibilities and infection-induced complications].
    Deutsche medizinische Wochenschrift (1946), 1993, May-28, Volume: 118, Issue:21

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Cyclophosphamide; Cy

1993
Treatment of locally recurrent male breast cancer by regional chemotherapy.
    The British journal of surgery, 1995, Volume: 82, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Chemotherapy, Cancer,

1995
TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer.
    Journal of medicine, 1994, Volume: 25, Issue:3-4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms

1994
Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
    Cancer, 1994, Aug-15, Volume: 74, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcino

1994
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
    Seminars in hematology, 1994, Volume: 31, Issue:2 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide

1994
Treatment of early stages of Hodgkin's disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy.
    Seminars in hematology, 1994, Volume: 31, Issue:2 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hodgkin Disease; Humans;

1994
Multimodal adjuvant treatment and liver transplantation for advanced hepatocellular carcinoma. A pilot study.
    Cancer, 1994, Jun-01, Volume: 73, Issue:11

    Topics: Adult; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Female; Foll

1994
Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma.
    European journal of gynaecological oncology, 1994, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Chromatography, Hig

1994
Intravesical mitoxantrone in superficial bladder tumours (Ta-T1).
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:13

    Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Cystitis; Humans; Mitoxantrone; Neoplasm

1993
Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy.
    Gynecologic oncology, 1993, Volume: 50, Issue:3

    Topics: Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Infusions, Parenter

1993
[Superselective intra-arterial chemotherapy in breast cancer].
    Der Radiologe, 1993, Volume: 33, Issue:5

    Topics: Adult; Aged; Angiography; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial; Mammary Arter

1993
Intravesical mitozantrone in recurrent superficial bladder cancer.
    British journal of urology, 1995, Volume: 76, Issue:6

    Topics: Administration, Intravesical; Antineoplastic Agents; Humans; Mitoxantrone; Neoplasm Recurrence, Loca

1995
[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1995, Volume: 163, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Cystadenocarcinoma; Drainage; Female; His

1995
Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation.
    Journal of cancer research and clinical oncology, 1996, Volume: 122, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Division; Combined Modality Therapy; Female; Hyperthermia, Indu

1996
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
    Blood, 1996, Mar-15, Volume: 87, Issue:6

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, CD7; Antineopla

1996
Late relapse after autologous BMT.
    Leukemia, 1996, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophospham

1996
Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.
    Journal of neuro-oncology, 1996, Volume: 27, Issue:2

    Topics: Adult; Antineoplastic Agents; Catheters, Indwelling; Chemotherapy, Cancer, Regional Perfusion; Elect

1996
A possible correlation between growth-factor sensitivity and response to mitoxantrone treatment in a murine myeloid leukaemia (SA7HD) cell line.
    Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:4

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Count; Cell Division; Culture Media, Conditioned;

1997
[Mitoxantrone-induced acute left heart failure after intrapleural administration].
    Herz, 1997, Volume: 22, Issue:4

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Dose-R

1997
[Preoperative irradiation and interstitial radiotherapy-hyperthermia boost in breast tumors > or = 3 cm. The Düsseldorf experience].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1997, Volume: 173, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A

1997
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:15

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1997
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne

1998
[High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer].
    Medicina clinica, 1997, Dec-06, Volume: 109, Issue:20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cyclophosphami

1997
High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
    Schweizerische medizinische Wochenschrift, 1998, Oct-03, Volume: 128, Issue:40

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm;

1998
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
    Cancer, 2000, May-01, Volume: 88, Issue:9

    Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Com

2000
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio

2000
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
    Italian journal of neurological sciences, 1999, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy

1999
Recurrent gastrointestinal stromal sarcomas.
    Surgical oncology, 2000, Volume: 9, Issue:2

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Humans; Injection

2000
Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy.
    Journal of chemotherapy (Florence, Italy), 2000, Volume: 12, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Axilla; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Combin

2000
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
    Revista espanola de medicina nuclear, 2001, Volume: 20, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combi

2001
Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study.
    Annals of hematology, 2001, Volume: 80, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogen

2001
Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia.
    Blood, 2002, May-15, Volume: 99, Issue:10

    Topics: Acute Disease; Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Ca

2002
Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
    European journal of haematology, 1992, Volume: 48, Issue:2

    Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cytar

1992
Leiomyosarcoma of the great saphenous vein.
    International orthopaedics, 1992, Volume: 16, Issue:2

    Topics: Combined Modality Therapy; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Mitoxantrone

1992
High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
    European journal of haematology, 1992, Volume: 48, Issue:2

    Topics: Adult; Bone Marrow Transplantation; Etoposide; Female; Heart Diseases; Hodgkin Disease; Humans; Male

1992
Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Acta haematologica, 1992, Volume: 87, Issue:1-2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Male;

1992
[Intravenous mitoxantrone use and simultaneous radiotherapy as a palliative treatment in recurrent head and neck tumors].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1991, Volume: 167, Issue:10

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy; Female; Head

1991
[Intra-arterial chemotherapy in locally advanced breast carcinomas].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1991, Volume: 155, Issue:1

    Topics: Adult; Angiography, Digital Subtraction; Breast Neoplasms; Female; Humans; Infusions, Intra-Arterial

1991
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
    European journal of haematology, 1991, Volume: 46, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubic

1991
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Blood, 1991, May-01, Volume: 77, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide;

1991
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea

1990
[Chemotherapy of highly malignant thyroid tumors].
    Wiener klinische Wochenschrift, 1990, Apr-27, Volume: 102, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Small Cell; Cisplatin; C

1990
Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors.
    The Journal of urology, 1990, Volume: 143, Issue:4

    Topics: Administration, Intravesical; Adult; Aged; Drug Evaluation; Female; Humans; Male; Middle Aged; Mitox

1990
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl

1990
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
    Cancer, 1990, Jun-15, Volume: 65, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Etoposide; Female; Humans; Infusions, Intravenous; Leuk

1990
Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study.
    American journal of hematology, 1990, Volume: 35, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Female; Humans; Le

1990
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
    Acta medica Austriaca, 1989, Volume: 16, Issue:3-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor

1989
Treatment with locally applied mitoxantrone.
    Acta medica Austriaca, 1989, Volume: 16, Issue:3-4

    Topics: Catheters, Indwelling; Female; Humans; Infusions, Parenteral; Male; Mediastinal Neoplasms; Mitoxantr

1989
[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1989, Jun-30, Volume: 109, Issue:19-21

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance

1989
[Tolerance of intraoperative, intraperitoneal chemotherapy in advanced gynecologic malignancies].
    Geburtshilfe und Frauenheilkunde, 1988, Volume: 48, Issue:8

    Topics: Adolescent; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female

1988
Phase II study of mitoxantrone in advanced or metastatic endometrial carcinoma.
    The Australian & New Zealand journal of obstetrics & gynaecology, 1987, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Aged; Drug Evaluation; Female; Humans; Middle Aged; Mitoxantrone; Neoplasm Recurrenc

1987
[Mitoxantrone in metastatic cylindromas. Apropos of a case].
    Bulletin du cancer, 1987, Volume: 74, Issue:1

    Topics: Adult; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitoxantrone; Neoplasm Recurrence, Loca

1987
Phase II study of high-dose mitoxantrone in the treatment of recurrent squamous cell carcinoma of the head and neck.
    American journal of clinical oncology, 1987, Volume: 10, Issue:4

    Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Drug Evaluation; Drug Tolerance; Female; Head and

1987
Mitoxantrone and advanced squamous cell carcinoma of the cervix: a Southwest Oncology Group Study.
    Cancer treatment reports, 1986, Volume: 70, Issue:4

    Topics: Adult; Aged; Anthraquinones; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Middle Aged;

1986
Mitoxantrone in advanced cervical carcinoma: a phase II study in patients not previously treated with chemotherapy.
    Cancer treatment reports, 1986, Volume: 70, Issue:10

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Hematologic Diseases; Humans; Middle

1986
Early and delayed clinical cardiotoxicity of doxorubicin.
    Cancer, 1985, Jun-15, Volume: 55, Issue:12

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo

1985
[Effects of combination chemotherapy M-VEMFH including mitoxantrone in advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1985